Asset Details
Do you wish to reserve the book?
New thiadiazole modified chitosan derivative to control the growth of human pathogenic microbes and cancer cell lines
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
New thiadiazole modified chitosan derivative to control the growth of human pathogenic microbes and cancer cell lines
Do you wish to request the book?
New thiadiazole modified chitosan derivative to control the growth of human pathogenic microbes and cancer cell lines
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
New thiadiazole modified chitosan derivative to control the growth of human pathogenic microbes and cancer cell lines
2022
Overview
The emergence of multidrug-resistant microbes and the propagation of cancer cells are global health issues. The unique properties of chitosan and its derivatives make it an important candidate for therapeutic applications. Herein, a new thiadiazole derivative, 4-((5-(butylthio)-1,3,4-thiadiazol-2-yl) amino)-4-oxo butanoic acid (BuTD-COOH) was synthesized and used to modify the chitosan through amide linkages, forming a new thiadiazole chitosan derivative (BuTD-CH). The formation of thiadiazole and the chitosan derivative was confirmed by FT-IR,
1
H/
13
C-NMR, GC–MS, TGA, Elemental analysis, and XPS. The BuTD-CH showed a high antimicrobial effect against human pathogens
Escherichia coli
,
Pseudomonas aeruginosa
,
Bacillus subtilis
,
Staphylococcus aureus
, and
Candida albicans
with low MIC values of 25–50 μg ml
−1
compared to unmodified chitosan. The in-vitro cytotoxicity of BuTD-CH was evaluated against two cancer cell lines (MCF-7 and HepG2) and one normal cell (HFB4) using the MTT method. The newly synthesized derivatives showed high efficacy against cancerous cells and targeted them at low concentrations (IC
50
was 178.9 ± 9.1 and 147.8 ± 10.5 μg ml
−1
for MCF-7 and HepG2, respectively) compared with normal HFB4 cells (IC
50
was 335.7 ± 11.4 μg ml
−1
). Thus, low concentrations of newly synthesized BuTD-CH could be safely used as an antimicrobial and pharmacological agent for inhibiting the growth of human pathogenic microbes and hepatocellular and adenocarcinoma therapy.
